Logo

Chugai Receives MHLW's Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)

Share this

Chugai Receives MHLW's Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)

Shots:

  • The MHLW has approved the expanded use of FoundationOne CDx for Rozlytrek to treat ROS1 fusion-positive- LA/ m-NSCLC- allowing the physician to identify NSCLC patients who could benefit from Rozlytrek by detecting ROS1 fusion genes
  • On Mar 15- 2019- Chugai has filed an application for the additional indication of Rozlytrek. Chugai will further expand the CDx functions of FoundationOne CDx for its in-house therapies and in collaboration with other biopharma partners
  • Rozlytrek is an oral tyrosine kinase inhibitor targeting ROS1 and TRK kinase activity- thus inhibiting the proliferation of cancer cells with ROS1 or NTRK gene fusions. FoundationOne CDx is a sequencing-based in vitro diagnostic device that detects mutations in 324 genes- select gene rearrangements and genomic signatures including MSI & TMB

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical  | Image:  Chugai Pharmaceutical


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions